Overview
Plain-language guide
Discussed or marketed in research-only contexts for Recovery claims, Gastrointestinal claims, Tendon and ligament claims. It is not approved for treating these uses.
It interacts with a specific cell-signaling pathway. The measured clinical effect depends on the exact molecule, formulation, population and quality of evidence.
Clinical mechanism
Proposed tissue-repair mechanisms remain largely preclinical and are not validated for human efficacy.
Applications
Human evidence
Validated human efficacy evidence is absent, limited or not independently replicated.
Tier 3Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Muscle & recovery profile
Each signal is scored independently from 0–5. There is no composite “best” score.
Evidence classes
What has been studied
- Animal and laboratory studies explore tendon, gastrointestinal and wound-healing pathways.
What is not established
- Human recovery, injury healing, muscle growth, dosing and long-term safety are not established.
Studied populations
- Preclinical models
Major limitations
- Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
- Findings from one population, formulation or indication should not be generalized to another.
Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.
Regulatory status
Unapproved / RUO. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Uncertain or Concerning
- Human safety data are incomplete
- Product identity, sterility and dose consistency may be unknown
Interactions
Combination data are sparse. Absence of documented interaction evidence is not evidence of compatibility.
Treatment pattern
No validated human dosing or cycling protocol exists.
Manufacturing and quality
RUO and grey-market products may not establish identity, net content, sterility, endotoxin control or cold-chain integrity.
Sponsor and development history
No approved-product sponsor · RUO. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- No validated human dosing or cycling protocol exists.
- Long-term safety and product-quality consistency remain unresolved.
Last reviewed
August 5, 2026 · Reviewed